Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis

Brain

Volumn 140, Issue 3, 2017, Pages 617-627

  Jurynczyk, Maciej ^a   Geraldes, Ruth ^a   Probert, Fay ^b   Woodhall, Mark R ^a   Waters, Patrick ^a   Tackley, George ^a   DeLuca, Gabriele ^a   Chandratre, Saleel ^a   Leite, Maria I ^a   Vincent, Angela ^a   Palace, Jacqueline ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Autoantibodies; Magnetic resonance imaging; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AQUAPORIN 4; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; BRAIN FOURTH VENTRICLE; BRAIN SCINTISCANNING; BRAIN STEM INJURY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; DEMYELINATING DISEASE; DISCRIMINANT ANALYSIS; FEMALE; GRAY MATTER; HUMAN; IMMUNOASSAY; LATERAL BRAIN VENTRICLE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL LEAST SQUARES REGRESSION; PONS; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AGE; BRAIN; DIAGNOSTIC IMAGING; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGE FACTORS; AQUAPORIN 4; AUTOANTIBODIES; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; PRINCIPAL COMPONENT ANALYSIS; RETROSPECTIVE STUDIES;

EID: 85028015842     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww350     Document Type: Article

References (37)

1. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86: 265–72.
2. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl) 1997; 75: 77–88.
3. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2’,3’-cyclic nucleotide 3’-phosphodiesterase in the CNS of adult rats. J Neurochem 1989; 52: 296–304.
4. von Büdingen H-C, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci USA 2002; 99: 8207–12.
5. Dale RC, Tantsis EM, Merheb V, Kumaran RY, Sinmaz N, Pathmanandavel K, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol. Neuroimmunol. neuroinflammation 2014; 1: e12.
6. Dickens AM, Larkin JR, Griffin JL, Matthews L, Turner MR, Wilcock GK, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 2015; 84: 2201.
7. Griffin JL, Anthony DC, Campbell SJ, Gauldie J, Pitossi F, Styles P, et al. Study of cytokine induced neuropathology by high resolution proton NMR spectroscopy of rat urine. FEBS Lett 2004; 568: 49–54.
8. Haase CG, Schmidt S. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic’s neuromyelitis optica. Neurosci Lett 2001; 307: 131–3.
9. Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015; 2: e81.
10. Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015; 21: 656–9.
11. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016; 22: 1541–9.
12. Juryn´czyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 2015; 86: 20–25.
13. Juryn´czyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016; 263: 140–9.
14. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015a; 84: 1165–73.
15. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015b; 2: e163.
16. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276–83.
17. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273–7.
18. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130: 443–54.
19. Makino T, Ito S, Mori M, Yonezu T, Ogawa Y, Kuwabara S. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler J 2013; 19: 308–15.
20. Marta CB, Bansal R, Pfeiffer SE. Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of myelin oligodendrocyte glycoprotein. J Neuroimmunol 2008; 196: 35–40.
21. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosy-lated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA 2005; 102: 13992–7.
22. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13: 211–17.
23. Poser CM, Brinar VV. Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review. Acta Neurol Scand 2007; 116: 201–6.
24. Pröbstel A-K, Rudolf G, Dornmair K, Collongues N, Chanson J-B, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 2015; 12: 1–7.
25. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122: 2047–56.
26. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMDH, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–81.
27. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139: 4016–21.
28. Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e257.
29. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom 2002; 16: 119–28.
30. Wang H, Munger KL, Reindl M, O’Reilly EJ, Levin LI, Berger T, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008; 71: 1142–6.
31. Waterman CL, Currie RA, Cottrell LA, Dow J, Wright J, Waterfield CJ, et al. An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics 2010; 11: 9.
32. Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2: e89.
33. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665–71; discussion 669.
34. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009; 66: 967–71.
35. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–15.
36. Xiao BG, Linington C, Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31: 91–6.
37. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 19057–62.